Abstract: This disclosure relates to methods of use related to omega-3 very-long-chain polyunsaturated fatty acids (n-3 VLC-PUFA) and their hydroxylated derivatives known as elovanoids to alleviate a symptom of, treat, or prevent disease. Furthermore, this invention is directed to compositions and methods for modulating VLC-PUFA bioactivity and availability.

Abstract: The present invention relates to a combination comprising cromoglicic acid or derivatives thereof and to dermatological compositions comprising said composition. The invention also relates to the use of said combination or composition for the treatment of dermatitis.

Abstract: A device for applying a powdered or particulate substance to a mucous membrane in a nostril comprises a tubular body (10) similar to a drinking straw. The tubular body has opposite end parts forming a mouthpiece (11) and a nasal piece (12) to be inserted between the lips and into the nostril, respectively, of a user. The mouthpiece (11) and the nasal piece (12) are interconnected by a bent or a bendable, preferably corrugated part (13). A dose of a powdered or particulate substance arranged within the tubular body (10) is transferred to the nostril when the user blows into the mouthpiece (11). A part of the mouthpiece is preferably deflated or compresses between a pair of fingers (35) of the user. The compressed part (34) is released when the user has started to blow forcefully into the compressed mouthpiece part which is thereby inflated. It has been found that the user will automatically close the connection between the nostrils and the throat by the uvula when blowing.

Abstract: A method and device for introducing a powdered or particulate substance into a person's nostril A device for applying a powdered or particulate substance to a mucous membrane in a nostril comprises a tubular body (10) similar to a drinking straw. The tubular body has opposite end parts forming a mouthpiece (11) and a nasal piece (12) to be inserted between the lips and into the nostril, respectively, of a user. The mouthpiece (11) and the nasal piece (12) are interconnected by a bent or a bendable, preferably corrugated part (13). A dose of a powdered or particulate substance arranged within the tubular body (10) is transferred to the nostril when the user blows into the mouthpiece (11). A part of the mouthpiece is preferably deflated or compresses between a pair of fingers (35) of the user. The compressed part (34) is released when the user has started to blow forcefully into the compressed mouthpiece part which is thereby inflated.

Abstract: A device for applying a powdered or particulate substance to a mucous membrane in a nostril comprises a tubular body (10) similar to a drinking straw. The tubular body has opposite end parts forming a mouthpiece (11) and a nasal piece (12) to be inserted between the lips and into the nostril, respectively, of a user. The mouthpiece (11) and the nasal piece (12) are interconnected by a bent or a bendable, preferably corrugated part (13). A dose of a powdered or particulate substance arranged within the tubular body (10) is transferred to the nostril when the user blows into the mouthpiece (11). A part of the mouthpiece is preferably deflated or compresses between a pair of fingers (35) of the user. The compressed part (34) is released when the user has started to blow forcefully into the compressed mouthpiece part which is thereby inflated. It has been found that the user will automatically close the connection between the nostrils and the throat by the uvula when blowing.

Abstract: Fimbriae adhesins have a molecular weight of 2×105 and 2×107 Da, and are comprised of 90-95% protein and 1-3% sugar. Type 1 fimbriae include five different protein fractions of 14-20 kDa, most of which are associated with carbohydrates. Type P fimbriae also include five different protein fractions of 14-20 kDa, and one of the majority proteins is associated with carbohydrates. The process of the invention comprises: culturing E. coli strains CECT 4484 and CECT 4485; collecting the sediment by centrifugation and resuspending it in physiological saline followed by homogenization; centrifuging the homogenate and collecting the supernatant; precipitating the supernatant with saline, reconstituting the precipitate and dialyzing the solution; treating the dialyzate with sodium deoxycholate and, subjecting the product to two successive chromatographies with Sephacryl S-200 and Sepharose 4B. The product is used for treatment and prevention of infections of the urinary tract caused by fimbriated E. coli.